Earnings Releases·Nov 12, 2026, 4:16 PM ET

Atrium Therapeutics — Third Quarter 2026 Earnings Summary

Collaboration revenue increased to $15.3 million year-over-year, driven by a $15.0 million milestone payment from Bristol Myers Squibb, while total operating expenses rose to $22.0 million and net loss widened to $4.3 million.
Pro-forma cash balance reached $293.6 million following a $50.0 million private placement and milestone payment, with management estimating these funds will support operations through 2028.
Corporate transition to a public entity was completed with 16,401 shares outstanding, resulting in a net loss per share of $0.25 compared to $0.00 in the prior year period.
Future outlook includes expected initial proof of concept data for the Corventis Phase 1/2 trial in the second half of 2027, an IND filing for ATR 1086 in 2027, and selection of a next development candidate for two undisclosed rare cardiomyopathy programs in 2027.